The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
about
sameAs
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acidsIntracellular metabolism of beta-L-2',3'-dideoxyadenosine: relevance to its limited antiviral activityEffect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucksAntiviral L-nucleosides specific for hepatitis B virus infectionThe polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceInfluence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profileCharacterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosidesThe 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptasePharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virusEvidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducksAnti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitroInhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidineUnique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytesMetabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitroAnti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.Synthesis and antiviral activity of C-5 substituted beta-D- and beta-L-D4T analogues.Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinaseCell-based and animal models for hepatitis B and C viruses.Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo modelPure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro.Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidineProfound suppression of hepatitis B virus replication with lamivudine.End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B.The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy?Anti-HBV specific beta-L-2'-deoxynucleosides.Evolving therapies for the treatment of chronic hepatitis B virus infection.Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay.Emerging therapies of hepatitis B and C.In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans.Agents in clinical development for the treatment of chronic hepatitis B.Antiviral therapy for human immunodeficiency virus infectionsHigh-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay.Emtricitabine (FTC) for the treatment of HIV infection.Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondriDiscovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC).
P2860
Q24682078-2E42B2D3-EBC4-425D-9FF8-D499BE97DD84Q28344037-E5523B0C-BD1F-42A8-92DD-AE4B273FCD2EQ28344296-D11C1C8B-F626-4399-AA2A-4682E7C56DA2Q28345251-773FA778-97D3-4051-9297-857163573FC4Q28350136-2FC6480F-ABCD-40A4-A4B2-347A2DD7A89EQ28367580-3F809009-723B-4708-B434-94B207E4D284Q28367605-1B451D59-243F-4300-9E7B-385EED575A35Q28368026-7B634F2C-91D6-4996-96E9-EAF31FCC78D0Q28368054-B26358DC-B61C-4BF6-91D7-EEFC33AFC242Q28368057-DF4D5EF4-4E54-4DC4-8AE7-1047689D56FEQ28369077-A7894374-6DBC-42D3-9C79-D000F4813425Q28369464-832CB986-B651-426B-B962-7E51C6890DFDQ28378787-3A89C8CF-10D8-4C18-8B02-EE78A8F2A983Q28378905-C4AFA866-6372-4948-8349-8F2001C541D9Q28379181-2D260D70-1C55-474A-96BF-33A886436F0BQ28379621-D89DF26A-1D33-4620-A899-7B65A70E7174Q28379623-B438EA27-8705-484E-AB24-7EF15D1A0188Q31618693-FBB77668-ED82-445C-8C5B-4135BC6AB0D7Q33692618-90C692FA-636E-451D-806C-5AC28E21C4F1Q33702348-B797D2C4-390E-4CB2-A52C-B3421DCE3CBAQ33751721-1F889937-E8D8-441A-99F4-193732F0F8FFQ33759430-D576B319-A06E-48C1-BD3B-7A8E5B330C54Q33808236-A55B6921-D235-4F66-8253-CB32173849D9Q33947154-8BD83018-F498-4A89-8213-D67B05DBA5DBQ33947177-FA6A3BAA-6713-435B-9422-0D13AABB4136Q33972465-37AA3B7C-CA16-404A-B16C-65BF0A2F2347Q34373564-57E968E3-FB40-47A9-971E-17C84F8AC872Q34519117-CD3D8B5C-B0CB-4F9A-ABCF-894B18284054Q34720217-7C20F018-DC4B-4CB0-BA61-FB21484574B0Q35048263-800E6E4F-D0A1-478B-8651-BB161DE4BC3DQ35122740-4EEEE68D-DC6D-4A21-8D91-7B600D4D9C6DQ35185749-0323F8A0-8371-494E-858A-3C3B107C3B20Q35366050-1F8FFDC5-8CDD-4AB9-AE48-940BA59EC1A5Q35810046-66BCCD04-95F5-4762-A567-05EA219C6E1CQ35810472-F762874E-E84F-4D6E-98BF-26864DCECFADQ35897545-AD77662E-E6B7-4343-914C-B1C21ED70EA6Q36328961-661F7532-45BF-40AF-AFC0-F96577DB6A91Q36607389-37017576-76A0-4F0D-B6C4-DED28A9C8F97Q37120519-5286A7B5-338B-455C-BA08-51B2AA76F120Q38405371-FA9D8659-41B5-4BEE-B00C-E7A135B740D1
P2860
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
description
1992 nî lūn-bûn
@nan
1992 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@ast
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@en
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@nl
type
label
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@ast
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@en
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@nl
prefLabel
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@ast
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@en
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@nl
P2093
P2860
P356
P1476
The anti-hepatitis B virus act ...... )-1,3-oxathiolan-5-yl]cytosine
@en
P2093
D C Liotta
D J Nelson
J A Wurster
L J Wilson
P A Furman
R E Dornsife
P2860
P304
P356
10.1128/AAC.36.12.2686
P407
P577
1992-12-01T00:00:00Z